CHMP gives positive opinion for fingolimod but turns back cladribine

Country

United Kingdom

The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion to Gilenya (fingolimod), Novartis’s oral, first-line treatment for relapsing multiple sclerosis. It received FDA approval in 2010.